Codexis (CDXS)
NASDAQ:CDXS
Want to see CDXS full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong top-line acceleration (Q1 revenue +≈103%), materially improved product margins (71% vs 55%), a substantially reduced net loss, promising platform innovations (stereochemical control) and a healthy sales funnel with CDMO interest. Offsetting these positives are reliance on a large one-time Merck revenue recognition for the quarter, a declining cash balance, remaining technical and scale-up risks (100 g to 0.5 kg target), and pending clinical/efficacy data to validate stereochemistry benefits. Management reiterated full-year guidance and expects the business to be operationally ready with a new GMP facility by end of 2027, but execution and partnership conversion timing will be critical.Company Guidance
Strong Revenue Growth
Total revenue of $15.2M in Q1 2026 versus $7.5M in Q1 2025, an increase of approximately 102.7%, driven primarily by recognition of revenue from the Merck technology transfer agreement.
Improved Product Gross Margin
Product gross margin improved to 71% in Q1 2026 from 55% in Q1 2025, a 16 percentage-point increase driven by favorable product mix and replacement of low-margin products.
Narrowed Net Loss
Net loss was $8.7M in Q1 2026 compared to a loss of $20.7M in Q1 2025, an improvement of $12.0M (≈58% reduction in the loss).
ECO Synthesis Technical Breakthroughs
ECO Synthesis platform now demonstrates stereochemical control at both 3' and 5' ends of siRNA, enabling stereopure products with potential for improved potency and product quality; data on stereochemistry to be presented at TIDES and additional activity data forthcoming.
Commercial Traction and Pipeline
Over 50 commercial opportunities in the sales pipeline across ~40 companies, active engagements with 3 CDMO partners (described as progressing positively), and multiple conversations with large and emerging drug developers.
Stable, Profitable Small-Molecule Biocatalysis Business
Small-molecule biocatalysis remains profitable and supports platform investments; Codexis supplies enzymes for 13 branded commercial pharmaceutical products and recently participated in a new approval (islatravir) with Merck.
Reiterated 2026 Guidance and Capital Plan
Reiterated 2026 revenue guidance of $72M to $76M and stated cash runway sufficient to fund operations and capital expenditures through the end of 2027, including GMP facility build-out.
Scale-Up Progress and Facility Plans
Operational scale: moving from lab scale to ~100 g and targeting 0.5 kg scale by year-end 2026; Hayward GMP facility retrofit design underway with permit application in Q2 2026 and expected operational readiness by end of 2027.
CDXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CDXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $2.58 | $2.85 | +10.47% |
Mar 11, 2026 | $1.27 | $1.71 | +34.65% |
Nov 06, 2025 | $2.04 | $1.69 | -16.95% |
Aug 13, 2025 | $3.05 | $3.10 | +1.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Codexis (CDXS) report earnings?
Codexis (CDXS) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Codexis (CDXS) earnings time?
Codexis (CDXS) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDXS EPS forecast?
CDXS EPS forecast for the fiscal quarter 2026 (Q2) is -0.14.